17 reports

RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE ## U. K. antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE ## U. K. antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million) TABLE ##

  • Antisense
  • Biological Therapy
  • Therapy
  • United States
  • Market Size
  • TOXICITY OF ANTISENSE AND RNAI MOLECULEBASED DRUGS
  • 76.94% OF THE MARKET SHARE COMES FROM ANTISENSE/RNAI

About Oligonucleotide Therapeutics Oligonucleotides are short nucleotides sequences of DNA or RNA molecules called oligomers. Oligonucleotide therapeutics target and inhibit the expression of certain diseases-causing genes, thus forming a new class of therapeutics to treat chronic diseases. Technavio’s analysts forecast...

  • Antisense
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • miRagen Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Antisense Therapeutics Ltd - Strengths
  • Antisense Therapeutics Ltd, History

Antisense Therapeutics Ltd (ANP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and...

  • Antisense
  • Therapy
  • World
  • Company Financials
  • Antisense Therapeutics Limited
  • Profitability Analysis: Antisense Therapeutics Limited
  • SUMMARY ANALYSIS: Antisense Therapeutics Limited

A textual analysis of the financial results for Antisense Therapeutics Limited compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business description of the company, including...

  • Antisense
  • United States
  • World
  • Company Financials
  • Antisense Therapeutics Limited
  • Antisense Therapeutics Ltd, Key Employees
  • Antisense Therapeutics Ltd - Key Employees

Summary Antisense Therapeutics Ltd (Antisense Therapeutics) is clinical staged biopharmaceutical company which focuses on the discovery, development and commercialization of second generation antisense pharmaceuticals for various medical conditions that have large unmet medical needs.It focuses on the development of antisense...

  • Antisense
  • Therapy
  • Australia
  • Deals & Alliance
  • Antisense Therapeutics Limited

Antisense Therapeutics Limited Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report ## Table of Contents ##. ## List of Tables ##. ## List of Figures ## Introduction to the Company ##. ## Antisense Therapeutics Limited- Key Findings ##. ##

  • Antisense
  • Therapy
  • Company
  • Antisense Therapeutics Limited Overview
  • Antisense Therapeutics Limited Snapshot

Antisense Therapeutics Limited - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Antisense Therapeutics Limited - Product Pipeline Review - 2015’, provides an overview of the Antisense Therapeutics Limited’s pharmaceutical research and development focus. This report provides comprehensive information...

  • Antisense
  • World
  • Company Operations
  • Product Initiative
  • Antisense Therapeutics Limited
  • JUL 24, 2012: ANTISENSE PHARMA RECEIVES FDA ORPHAN DRUG DESIGNATION FOR TRABEDERSEN TO TREAT MALIGNANT MELANOMA
  • MAR 01, 2016: ONCOTELIC PRESENTS TREATMENT WITH TRABEDERSEN- AN ANTI-TGF-BETA-2 ANTISENSE- PRIMED TUMORS TO SUBSEQUENT CHEMOTHERAPIES

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H1 2017 Summary According to the recently published report 'Transforming Growth Factor Beta 2 - Pipeline Review, H1 2017'; Transforming Growth Factor Beta...

  • Antisense
  • Brain Cancer
  • World
  • Product Initiative
  • Isarna Therapeutics GmbH
  • JUN 04, 2012: ANTISENSE PHARMA PRESENTS TRABEDERSEN PHASE I/II COMPLETE DATA AT ASCO ANNUAL MEETING
  • MAR 01, 2016: ONCOTELIC PRESENTS TREATMENT WITH TRABEDERSEN- AN ANTI-TGF-BETA-2 ANTISENSE- PRIMED TUMORS TO SUBSEQUENT CHEMOTHERAPIES

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H2 2017 Summary Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin...

  • Antisense
  • Brain Cancer
  • World
  • Product Initiative
  • Isarna Therapeutics GmbH
  • 03/15/2018: Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting
  • Mar 10, 2017: Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting

Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers.The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) and BP1002 (Liposomal...

  • Antisense
  • Therapy
  • United States
  • Company
  • Ogden Golf Co.

Interest on the notes is payable semi-annually in arrears on April ## and October ## of each year, commencing from October ##, 2012.

  • Antisense
  • Antisense Technology
  • United States
  • Company
  • Ionis Pharmaceuticals, Inc.
  • ANTISENSE THERAPEUTICS LIMITED
  • RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) - PIPELINE BY ANTISENSE THERAPEUTICS LIMITED, H2 2016

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2016, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) (Central...

  • Antisense
  • Monoclonal Antibody
  • Neurological Disorder
  • Therapy
  • AB Science SA
  • Ionis Pharmaceuticals Inc - Strengths
  • SWOT Analysis - Overview

Ionis Pharmaceuticals Inc (IONS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and...

  • Antisense
  • Pharmaceutical
  • United States
  • Company Financials
  • Ionis Pharmaceuticals, Inc.
  • ANTISENSE RNAI OLIGONUCLEOTIDE FOR LIVER FIBROSIS - DRUG PROFILE
  • ANTISENSE RNAI OLIGONUCLEOTIDE FOR LIVER FIBROSIS - DRUG PROFILE

Liver Fibrosis - Pipeline Review, H1 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Liver Fibrosis - Pipeline Review, H1 2017, provides an overview of the Liver Fibrosis (Gastrointestinal) pipeline landscape. Liver fibrosis is a scarring process which results...

  • Antisense
  • United States
  • World
  • Product Initiative
  • Galectin Therapeutics Inc.
  • PIPELINE BY GENZYME CORP, H1 2018

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Antisense
  • Ophthalmology
  • Therapy
  • Product Initiative
  • Isarna Therapeutics GmbH
  • IONIS PHARMACEUTICALS, INC.: COMPANY ANALYSIS
  • IONIS PHARMACEUTICALS, INC.: COMPANY HISTORY

Ionis Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ionis Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and...

  • Antisense
  • Pharmaceutical
  • United States
  • Company
  • Ionis Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
  • Ionis Pharmaceuticals, Inc. - Company Statement

Ionis Pharmaceuticals, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Ionis Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Ionis Pharmaceuticals, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on...

  • Antisense
  • Pharmaceutical
  • United States
  • Company Operations
  • Ionis Pharmaceuticals, Inc.